Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 78

1.

Perifosine treatment in chronic lymphocytic leukemia: results of a phase II clinical trial and in vitro studies.

Friedman DR, Lanasa MC, Davis PH, Allgood SD, Matta KM, Brander DM, Chen Y, Davis ED, Volkheimer AD, Moore JO, Gockerman JP, Sportelli P, Weinberg JB.

Leuk Lymphoma. 2014 May;55(5):1067-75. doi: 10.3109/10428194.2013.824080. Epub 2013 Aug 31.

PMID:
23863122
2.

Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.

Plosker GL, Figgitt DP.

Drugs. 2003;63(8):803-43. Review.

PMID:
12662126
3.

Clinical and translational studies of a phase II trial of the novel oral Akt inhibitor perifosine in relapsed or relapsed/refractory Waldenstrom's macroglobulinemia.

Ghobrial IM, Roccaro A, Hong F, Weller E, Rubin N, Leduc R, Rourke M, Chuma S, Sacco A, Jia X, Azab F, Azab AK, Rodig S, Warren D, Harris B, Varticovski L, Sportelli P, Leleu X, Anderson KC, Richardson PG.

Clin Cancer Res. 2010 Feb 1;16(3):1033-41. doi: 10.1158/1078-0432.CCR-09-1837. Epub 2010 Jan 26.

4.

Phase II study of perifosine and sorafenib dual-targeted therapy in patients with relapsed or refractory lymphoproliferative diseases.

Guidetti A, Carlo-Stella C, Locatelli SL, Malorni W, Mortarini R, Viviani S, Russo D, Marchianò A, Sorasio R, Dodero A, Farina L, Giordano L, Di Nicola M, Anichini A, Corradini P, Gianni AM.

Clin Cancer Res. 2014 Nov 15;20(22):5641-51. doi: 10.1158/1078-0432.CCR-14-0770. Epub 2014 Sep 19.

5.

In vitro and in vivo inhibition of neuroblastoma tumor cell growth by AKT inhibitor perifosine.

Li Z, Tan F, Liewehr DJ, Steinberg SM, Thiele CJ.

J Natl Cancer Inst. 2010 Jun 2;102(11):758-70. doi: 10.1093/jnci/djq125. Epub 2010 May 12.

6.

Perifosine--a new option in treatment of acute myeloid leukemia?

Krawczyk J, Keane N, Swords R, O'Dwyer M, Freeman CL, Giles FJ.

Expert Opin Investig Drugs. 2013 Oct;22(10):1315-27. doi: 10.1517/13543784.2013.826648. Epub 2013 Aug 9. Review.

PMID:
23931614
7.

A phase I study of imatinib mesylate in combination with chlorambucil in previously treated chronic lymphocytic leukemia patients.

Hebb J, Assouline S, Rousseau C, Desjardins P, Caplan S, Egorin MJ, Amrein L, Aloyz R, Panasci L.

Cancer Chemother Pharmacol. 2011 Sep;68(3):643-51. doi: 10.1007/s00280-010-1530-7. Epub 2010 Dec 1.

PMID:
21120481
8.

A phase II trial of perifosine, an oral alkylphospholipid, in recurrent or metastatic head and neck cancer.

Argiris A, Cohen E, Karrison T, Esparaz B, Mauer A, Ansari R, Wong S, Lu Y, Pins M, Dancey J, Vokes E.

Cancer Biol Ther. 2006 Jul;5(7):766-70. Epub 2006 Jul 2.

PMID:
16760642
9.

Perifosine, an AKT inhibitor, modulates ovarian cancer cell line sensitivity to cisplatin-induced growth arrest.

Al Sawah E, Chen X, Marchion DC, Xiong Y, Ramirez IJ, Abbasi F, Bou Zgheib N, Chon HS, Wenham RM, Apte SM, Judson PL, Lancaster JM.

Gynecol Oncol. 2013 Oct;131(1):207-12. doi: 10.1016/j.ygyno.2013.07.088. Epub 2013 Jul 20.

PMID:
23877012
10.

A phase I/Ib trial targeting the Pi3k/Akt pathway using perifosine: Long-term progression-free survival of patients with resistant neuroblastoma.

Kushner BH, Cheung NV, Modak S, Becher OJ, Basu EM, Roberts SS, Kramer K, Dunkel IJ.

Int J Cancer. 2017 Jan 15;140(2):480-484. doi: 10.1002/ijc.30440. Epub 2016 Sep 30.

PMID:
27649927
11.

Treatment of relapsed chronic lymphocytic leukemia by 72-hour continuous infusion or 1-hour bolus infusion of flavopiridol: results from Cancer and Leukemia Group B study 19805.

Byrd JC, Peterson BL, Gabrilove J, Odenike OM, Grever MR, Rai K, Larson RA; Cancer and Leukemia Group B.

Clin Cancer Res. 2005 Jun 1;11(11):4176-81.

12.

The alkylphospholipid perifosine induces apoptosis of human lung cancer cells requiring inhibition of Akt and activation of the extrinsic apoptotic pathway.

Elrod HA, Lin YD, Yue P, Wang X, Lonial S, Khuri FR, Sun SY.

Mol Cancer Ther. 2007 Jul;6(7):2029-38. Epub 2007 Jun 29.

13.

Two phase 2 trials of the novel Akt inhibitor perifosine in patients with advanced renal cell carcinoma after progression on vascular endothelial growth factor-targeted therapy.

Cho DC, Hutson TE, Samlowski W, Sportelli P, Somer B, Richards P, Sosman JA, Puzanov I, Michaelson MD, Flaherty KT, Figlin RA, Vogelzang NJ.

Cancer. 2012 Dec 15;118(24):6055-62. doi: 10.1002/cncr.27668. Epub 2012 Jun 6.

14.

Perifosine inhibits growth of human experimental endometrial cancers by blockade of AKT phosphorylation.

Engel JB, Honig A, Schönhals T, Weidler C, Häusler S, Krockenberger M, Grunewald TG, Dombrowski Y, Rieger L, Dietl J, Wischhusen J.

Eur J Obstet Gynecol Reprod Biol. 2008 Nov;141(1):64-9. doi: 10.1016/j.ejogrb.2008.06.007. Epub 2008 Aug 6.

PMID:
18687514
15.

Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation.

Kondapaka SB, Singh SS, Dasmahapatra GP, Sausville EA, Roy KK.

Mol Cancer Ther. 2003 Nov;2(11):1093-103.

16.

Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor perifosine in acute myelogenous leukemia cells.

Papa V, Tazzari PL, Chiarini F, Cappellini A, Ricci F, Billi AM, Evangelisti C, Ottaviani E, Martinelli G, Testoni N, McCubrey JA, Martelli AM.

Leukemia. 2008 Jan;22(1):147-60. Epub 2007 Oct 11.

PMID:
17928881
17.

In vitro combination treatment with perifosine and UCN-01 demonstrates synergism against prostate (PC-3) and lung (A549) epithelial adenocarcinoma cell lines.

Dasmahapatra GP, Didolkar P, Alley MC, Ghosh S, Sausville EA, Roy KK.

Clin Cancer Res. 2004 Aug 1;10(15):5242-52.

18.

Akt inhibitors induce apoptosis in chronic lymphocytic leukemia cells.

de Frias M, Iglesias-Serret D, Cosialls AM, Coll-Mulet L, Santidrián AF, González-Gironès DM, de la Banda E, Pons G, Gil J.

Haematologica. 2009 Dec;94(12):1698-707. doi: 10.3324/haematol.2008.004028. Epub 2009 Oct 8.

19.

Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia.

Brown JR, Byrd JC, Coutre SE, Benson DM, Flinn IW, Wagner-Johnston ND, Spurgeon SE, Kahl BS, Bello C, Webb HK, Johnson DM, Peterman S, Li D, Jahn TM, Lannutti BJ, Ulrich RG, Yu AS, Miller LL, Furman RR.

Blood. 2014 May 29;123(22):3390-7. doi: 10.1182/blood-2013-11-535047. Epub 2014 Mar 10.

20.

Perifosine: update on a novel Akt inhibitor.

Gills JJ, Dennis PA.

Curr Oncol Rep. 2009 Mar;11(2):102-10. Review.

PMID:
19216841

Supplemental Content

Support Center